Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

被引:88
|
作者
D'Alto, Michele [1 ]
Romeo, Emanuele [1 ]
Argiento, Paola [1 ]
Sarubbi, Berardo [1 ]
Santoro, Giuseppe [1 ]
Grimaldi, Nicola [1 ]
Correra, Anna [1 ]
Scognamiglio, Giancarlo [1 ]
Russo, Maria Giovanna [1 ]
Calabro, Raffaele [1 ]
机构
[1] Univ Naples 2, Dept Cardiol, Monaldi Hosp, Naples, Italy
关键词
Pulmonary arterial hypertension; Congenital heart disease; Association therapy; IMPROVES FUNCTIONAL-CAPACITY; ORAL SILDENAFIL; COMBINATION THERAPY; INHALED ILOPROST; CLINICAL-TRIAL; ADULT PATIENTS; 6-MINUTE WALK; OPEN-LABEL; EFFICACY; TOLERABILITY;
D O I
10.1016/j.ijcard.2010.10.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. Methods: Thirty-two patients with CHD-related PAH (14 male, mean age 37.1 +/- 13.7 years) treated with oral bosentan underwent right heart catheterization (RHC) for clinical worsening. After RHC, all patients received oral sildenafil 20 mg thrice daily in addition to bosentan. Clinical status, resting transcutaneous oxygen saturation (SpO(2)), 6-minute walk test (6MWT), serology and RHC were assessed at baseline (before add-on sildenafil) and after 6 months of combination therapy. Results: Twelve patients had ventricular septal defect, 8 atrio-ventricular canal, 6 single ventricle, and 6 atrial septal defect. Twenty-eight/32 had Eisenmenger physiology and 4 (all with atrial septal defect) did not. All patients well tolerated combination therapy. After 6 months of therapy, an improvement in clinical status (WHO functional class 2.1 +/- 0.4 vs 2.9 +/- 0.3; P=0.042), 6-minute walk distance (360 +/- 51 vs 293 +/- 68 m; P=0.005), SpO(2) at the end of the 6MWT (72 +/- 10 vs 63 +/- 15%; P=0.047), Borg score (2.9 +/- 1.5 vs 4.4 +/- 2.3; P=0.036), serology (pro-brain natriuretic peptide 303 +/- 366 vs 760 +/- 943 pg/ml; P=0.008) and haemodynamics (pulmonary blood flow 3.4 +/- 1.0 vs 3.1 +/- 1.2 l/min/m(2), P=0.002; pulmonary vascular resistances index 19 +/- 9 vs 24 +/- 16 WU/m(2), P=0.003) was observed. Conclusions: Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up, resulting in a significant improvement in clinical status, effort SpO(2), exercise tolerance and haemodynamics. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:378 / 382
页数:5
相关论文
共 50 条
  • [11] Efficacy and Safety of Bosentan for Pulmonary Arterial Hypertension in Adults With Congenital Heart Disease
    Monfredi, Oliver
    Griffiths, Linda
    Clarke, Bernard
    Mahadevan, Vaikom S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (10) : 1483 - 1488
  • [12] From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?
    Blok, Ilja M.
    van Riel, Annelieke C. M. J.
    van Dijk, Arie P. J.
    Mulder, Barbara J. M.
    Bouma, Berto J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 227 : 51 - 52
  • [13] Exercise ventilatory reserve predicts survival in adult congenital heart disease associated pulmonary arterial hypertension with Eisenmenger physiology
    Samaranayake, Chinthaka B.
    Mcniven, Ruth
    Kempny, Aleksander
    Harries, Carl
    Price, Laura C.
    Gatzoulis, Michael
    Dimopoulos, Konstantinos
    Wort, Stephen J.
    Mccabe, Colm
    INTERNATIONAL JOURNAL OF CARDIOLOGY CONGENITAL HEART DISEASE, 2022, 7
  • [14] Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
    Krishnan, Usha
    Rosenzweig, Erika B.
    CLINICS IN CHEST MEDICINE, 2013, 34 (04) : 707 - +
  • [15] Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy
    Porhownik, Nancy R.
    Al-Sharif, Hassan
    Bshouty, Zoheir
    CANADIAN RESPIRATORY JOURNAL, 2008, 15 (08) : 427 - 430
  • [16] Transpulmonary Expression of Exosomal microRNAs in Idiopathic and Congenital Heart Disease-Related Pulmonary Arterial Hypertension
    Chang, Wei-Ting
    Lee, Wei-Chieh
    Lin, Yu-Wen
    Shih, Jhih-Yuan
    Hong, Chon-Seng
    Chen, Zhih-Cherng
    Chu, Chun-Yuan
    Hsu, Chih-Hsin
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (23):
  • [17] Adult congenital heart disease with pulmonary arterial hypertension: mechanisms and management
    Papamichalis, Michail
    Xanthopoulos, Andrew
    Papamichalis, Panagiotis
    Skoularigis, John
    Triposkiadis, Filippos
    HEART FAILURE REVIEWS, 2020, 25 (05) : 773 - 794
  • [18] Pulmonary Arterial Hypertension Complicating Congenital Heart Disease: Advances in Therapy
    Nashat, Heba
    Brida, Margarita
    Price, Laura S.
    McCabe, Colm
    Alonso-Gonzalez, Rafael
    Wort, Stephen J.
    Kempny, Aleksander
    Dimopoulos, Konstantinos
    Gatzoulis, Michael J.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 38 (05) : 636 - 650
  • [19] Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease
    Condliffe, R.
    Clift, P.
    Dimopoulos, K.
    Tulloh, R. M. R.
    PULMONARY CIRCULATION, 2018, 8 (03)
  • [20] Bosentan combined with sildenafil in the treatment of COPD patients with pulmonary arterial hypertension
    Li, Ying
    Wang, Yao
    Liu, Shaohua
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (10): : 11522 - 11530